The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi ...

Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Prothena Corporation plc's phase 3 trial failure in AL Amyloidosis was a setback, but Alzheimer's & Parkinson's data could change things. Click for my PRTA update.

Aortic valve narrowing (aortic stenosis) with concomitant cardiac amyloidosis is a severe heart disease of old age that is ...

MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...

Prothena has made the decision to discontinue the AFFIRM-AL trial, including the open-label extension portion.

Prothena halts birtamimab development after Phase 3 trial fails to meet endpoints in AL amyloidosis patients; cost cuts and ...